Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience

Lim, 2016, Epidemiology and burden of multidrug-resistant bacterial infection in a developing country, Elife, 5, e18082, 10.7554/eLife.18082 Prestinaci, 2015, Antimicrobial resistance: a global multifaceted phenomenon, Pathog Glob Health, 109, 309, 10.1179/2047773215Y.0000000030 Sternbach, 2018, Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis, J Antimicrob Chemother, 73, 2021, 10.1093/jac/dky124 Wagenlehner, 2019, Once-daily plazomicin for complicated urinary tract infections, N Engl J Med, 380, 729, 10.1056/NEJMoa1801467 Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect Dis, 21, 226, 10.1016/S1473-3099(20)30796-9 2020 2020 Sato, 2019, Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin, Clin Infect Dis, 69, S538, 10.1093/cid/ciz826 Wu, 2020, Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms, Infect Dis Ther, 9, 17, 10.1007/s40121-020-00286-6 Abdul-Mutakabbir, 2020, Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant Gram-negative pathogens, Pharmacotherapy, 40, 1228, 10.1002/phar.2476 Zhanel, 2019, Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli, Drugs, 79, 271, 10.1007/s40265-019-1055-2 Portsmouth, 2018, Cefiderocol versus imipenem–cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 18, 1319, 10.1016/S1473-3099(18)30554-1 Wunderink, 2021, Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis, 21, 213, 10.1016/S1473-3099(20)30731-3 Bleibtreu, 2021, The Cefiderocol French Study Group. Susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study, Microorganisms, 9, 282, 10.3390/microorganisms9020282 Falcone, 2021, Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients, Clin Infect Dis, 72, 2021, 10.1093/cid/ciaa1410 Bavaro, 2021, Cefiderocol-based combination therapy for ‘difficult-to-treat’ Gram-negative severe infections: real-life case series and future perspectives, Antibiotics (Basel), 10, 652, 10.3390/antibiotics10060652 Falcone, 2022, Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 66, 10.1128/aac.02142-21 Katsube, 2017, Cefiderocol, a siderophore cephalosporin for Gram negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment, J Clin Pharmacol, 57, 584, 10.1002/jcph.841 Perez, 2007, Global challenge of multidrug-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 51, 3471, 10.1128/AAC.01464-06 Durante-Mangoni, 2016, Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections, Clin Microbiol Infect, 22, 984, 10.1016/j.cmi.2016.08.004